<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980456</url>
  </required_header>
  <id_info>
    <org_study_id>CLY935-C019</org_study_id>
    <nct_id>NCT04980456</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses</brief_title>
  <official_title>Clinical Assessment of Two Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical performance of TOTAL30 contact lenses&#xD;
      with Biofinity contact lenses over 30 days of daily wear.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will wear two products and be expected to attend 4 office visits. The individual&#xD;
      duration of participation will be approximately 65 days (which includes 30 days for each&#xD;
      product).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance Visual Acuity (logMAR) with study lenses</measure>
    <time_frame>Day 30, each product</time_frame>
    <description>Visual acuity will be assessed with letter charts</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>TOTAL30, then Biofinity</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for nightly cleaning and disinfection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biofinity, then TOTAL30</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for nightly cleaning and disinfection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lehfilcon A contact lenses</intervention_name>
    <description>Investigational silicone hydrogel contact lenses</description>
    <arm_group_label>Biofinity, then TOTAL30</arm_group_label>
    <arm_group_label>TOTAL30, then Biofinity</arm_group_label>
    <other_name>TOTAL30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comfilcon A contact lenses</intervention_name>
    <description>Commercially available silicone hydrogel contact lenses</description>
    <arm_group_label>Biofinity, then TOTAL30</arm_group_label>
    <arm_group_label>TOTAL30, then Biofinity</arm_group_label>
    <other_name>CooperVision® Biofinity®</other_name>
    <other_name>Biofinity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CLEAR CARE</intervention_name>
    <description>Hydrogen peroxide-based cleaning and disinfecting solution</description>
    <arm_group_label>Biofinity, then TOTAL30</arm_group_label>
    <arm_group_label>TOTAL30, then Biofinity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand and sign an approved Informed Consent form;&#xD;
&#xD;
          -  Willing and able to attend all scheduled study visits as required by the protocol;&#xD;
&#xD;
          -  Currently wearing any commercial spherical weekly/monthly soft contact lenses in both&#xD;
             eyes for at least 3 months, minimum 5 days per week, 10 hours per day;&#xD;
&#xD;
          -  Manifest cylinder less than or equal to 0.75 diopter (D) in each eye;&#xD;
&#xD;
          -  Willing to stop wearing habitual contact lenses for the duration of study&#xD;
             participation.&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any eye condition that contraindicates contact lens wear, as determined by the&#xD;
             Investigator;&#xD;
&#xD;
          -  Any use of systemic or ocular medicine that contraindicates contact lens wear, as&#xD;
             determined by the Investigator;&#xD;
&#xD;
          -  Ocular or intraocular surgery (excluding placement of punctal plugs) within the&#xD;
             previous 12 months or planned during the study;&#xD;
&#xD;
          -  Any use of topical ocular medications and artificial tear or rewetting drops that&#xD;
             would require instillation during contact lens wear;&#xD;
&#xD;
          -  Current or prior Biofinity contact lens wear in the past 3 months prior to consent.&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Lead, Vision Care</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigator 8135</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8062</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8106</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6356</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <zip>32779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6565</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6654</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6567</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 5582</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8097</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 7980</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8130</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6401</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02888</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6353</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 8175</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact lenses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

